机构：[1]Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Clinical Research Institute, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.[2]Department of Intensive Care Unit, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Immunomodulatory drugs (IMiDs) are widely used in the management of newly diagnosed and relapsed/refractory multiple myeloma patients. These agents show their potential effect on myeloma bone disease (MBD), including inhibition of osteoclasts activity and effects on osteoblasts differentiation. It is unclear whether these effects are direct, which may have an impact on bone formation markers when combined with proteasome inhibitors.This review summarizes the available evidence on the role of IMiDs in microenvironment regulation and their potential effects on bone metabolism. The literature search methodology consisted of searching PubMed for basic and clinical trials using medical subject terms. Included articles were screened and evaluated by the coauthors of this review.As a therapeutic option, IMiDs directly affect preosteoblast/osteoclast differentiation. The combination of proteasome inhibitors may counteract the short-term up-regulation of osteogenic activity markers, and therefore intravenous zoledronic acid is recommended, however, obtaining a more significant myeloma response will have a long-term positive impact on myeloma bone disease.
基金：
Luzhou Municipal Government—Southwest Medical University Cooperation Application Foundation (grant no.2023LZXNYDJ045) and Academic Research Projects of Southwest Medical University (grant no. 2023QN042).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|4 区医学
小类|4 区血液学
第一作者：
第一作者机构：[1]Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Clinical Research Institute, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Yang,Li Bo,Chen Xiaomin,et al.The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma[J].Expert Review Of Hematology.2024,17(1-3):47-54.doi:10.1080/17474086.2024.2316090.
APA：
Liu Yang,Li Bo,Chen Xiaomin,Xiong Hao&Huang Chunlan.(2024).The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.Expert Review Of Hematology,17,(1-3)
MLA：
Liu Yang,et al."The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma".Expert Review Of Hematology 17..1-3(2024):47-54
：